Aptose biosciences inc. (APTO)
Income statement / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Sep'17Jun'17
Expenses:
Revenue

-

-

-

-

-

-

-

-

-

0

0

Research and development

19,429

16,835

15,766

14,606

18,933

18,733

0

0

0

0

0

General and administrative

13,662

10,022

9,532

9,276

8,932

10,374

0

0

0

0

0

Operating expenses

33,091

26,857

25,298

23,882

27,865

29,107

0

0

0

-

-

Other income (expense):
Interest income

805

574

492

385

331

283

0

0

0

-

-

Foreign exchange gains/( losses)

-11

6

-23

-19

-26

-44

0

0

0

-

-

Total other income

794

580

469

366

305

239

0

0

0

-

-

Net loss

-32,297

-26,277

-24,829

-23,516

-27,560

-28,868

0

0

0

-

-

Other comprehensive loss:
Unrealized gain/(loss) on securities available-for-sale

-

18

0

0

0

-

0

0

0

-

-

Total comprehensive loss

-32,288

-26,259

-24,819

-23,492

-27,549

-28,868

0

0

0

-

-

Basic and diluted loss per common share (in dollars per share)

-0.15

-0.13

-0.12

-0.13

-0.14

-0.17

-0.16

-0.30

-0.23

-

-

Weighted average number of common shares outstanding used in the calculation of (in thousands) Basic and diluted loss per common share (in shares)

76,227

58,866

55,454

46,474

39,846

35,985

34,587

33,950

29,042

-

-

Operating Expenses

-

-

-

-

-

-

-

-

-

0

0

Finance expense (note 9)

-

-

-

-

-

-

-

-

-

0

0

Finance income (note 9)

-

-

-

-

-

-

-

-

-

0

0

Net finance income

-

-

-

-

-

-

-

-

-

0

0

Net loss and comprehensive loss for the period

-

-

-

-

-

-

-

-

-

0

0

Basic and diluted loss per common share (in dollars per share)

-

-

-

-

-

-

-

-

-

-0.11

-0.11

Weighted average number of common shares outstanding used in the calculation of basic and diluted loss per common share (000s) note 6(b) (in shares)

-

-

-

-

-

-

-

-

-

24,061

21,309